


## Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

### SUPPLEMENTARY MATERIALS



**Supplementary Figure 1: The number of CD163+ cells in in-transit melanoma.** The number of immunoreactive cells was counted using an ocular grid of 1 cm<sup>2</sup> at a magnification of 400x. The data are expressed as the means ± SDs of the numbers in each area. For a single comparison of two groups, the Mann–Whitney *U*-test or Student's *t*-test was used ( $p < 0.05$ ).